Views
4 years ago

95 - D Serrani - Noviembre 2015

  • Text
  • Resistente
  • Nota
  • Psico
  • Semanas
  • Quetiapina
  • Lithium
  • Lamotrigina
  • Pramipexol
  • Quetiapine
  • Tratamiento
  • Riluzole
  • Pacientes
  • Bipolar
Potenciación con riluzole y pramipexol en pacientes con depresión bipolar no respondedores a lamotrigina-quetiapinalitio: resultados de un ensayo abierto de 16 semanas

Dr. Daniel

Dr. Daniel Serrani Conclusiones La combinación de QTP/Li + LTG + RLZ + PMX se asoció con un efecto beneficioso en el humor de los pacientes con depresión bipolar resistente y parece ser una combinación bien tolerada con cambios menores en el peso corporal. Estos resultados enfatizan el beneficio potencial de la combinación de potenciación de riluzole por encima de pramipexol para depresión bipolar refractaria. Sin embargo, son necesarios estudios doble ciego para confirmar la eficacia de esta combinación así como la seguridad, la eficacia y la tolerabilidad en depresión bipolar. Bibliografía - Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manicdepressive ill¬ness. A comparison with lithium. Acta Psychiatr Scand. 1981; 64:226-237. - Altshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry. 2006; 163:313-315. - Bobes, J., Bulbena, A., Luque, A., Dal-Ré, R., Ballesteros, J., & Ibarra, N. A comparative psychometric study of the Spanish versions with 6, 17, and 21 items of the Hamilton Depression Rating Scale. Medicina clínica 2003, 120(18): 693-700. - Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003; 60:392-400. - Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005; 66:111-121. - Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003; 64: 1013-1024. - Calabrese JR, Bowden CL, Sachs GS, et al. Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 1999; 60:79-88. - Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005; 162:1351-1360. - Colom F, Vieta E, Martinez-Arán A, García- García M, Reinares M, Torrent C, Goikolea, JM, Banús S, Salamero M. Versión española de una escala de evaluación de la manía: validez y fiabilidad de la Escala Young. Medicina Clínica 2002; 119(10): 366-71. - Dilsaver SC, Chen YW, Swann AC, et al. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and puremania. Psychiatry Res. 1997; 73:47-56. - First, M.B., Spitzer, R.L., Williams, J.B.W., & Gibbon, M. Entrevista Clínica Estructurada para los Trastornos del Eje I del DSM-IV, Versión Clínica (SCID-I-VC). 1999. Barcelona: Masson Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials. Br J Psychiatry 2009; 194:4–9. - Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller H, Kasper S. WFSBP Task Force On Treatment Guidelines For Bipolar Disorders, WFSBP Task Force On Treatment Guidelines For Bipolar Disorders The World Journal of Biological Psychiatry 2010; 11(2): 81-109. - Guy W: Clinical Global Impressions (CGI) Scale. Modified From: Rush J, et al.: Psychiatric Measures, APA, Washington DC, 2000. - Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003; 60:261-269. - Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005; 62:1322-1330. - Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002; 59:530-537. - Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982; 39:473-481. - Kupfer DJ, Frank E, Grochocinski VJ, et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry. 2002; 63:120-125. - McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005; 15:573-585. - Pacchiarotti, I., Mazzarini, L., Colom, F., Sanchez‐Moreno, J., Girardi, P., Kotzalidis, G. D., & Vieta, E. Treatment‐resistant bipolar depression: towards a new definition. Acta Psychiatrica Scandinavica 2009, 120(6), 429-440. - Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2004; 6:213-223. - Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003; 53:1028-1042. - Sienaert P, Lambrichts L, Dols A, De Fruyt J. Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review. Bipolar Disorders 2013, 15(1): 61-69. - Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry. 2009; 166:476- 488. - Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006; 26:600-609. - Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600-609. - Tollefson GD, Beasley CM Jr, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 1997; 154:1248-1254. - Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008; 109:251-263. - Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 2004; 24:599- 606. - Zarate CA Jr. Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biological Psychiatry 2005; 57:430–2. 16 // EDITORIAL SCIENS

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015